Researchers examined patients with acute branch atheromatous disease to compare two treatment approaches. One group received early tirofiban plus aspirin, while the other received standard dual antiplatelet therapy. The main goal was to see if the first approach prevented early neurological deterioration within the first week and improved long-term function.
The analysis found that early neurological deterioration occurred in 10.1% of patients receiving tirofiban plus aspirin, compared to 55.1% in the dual antiplatelet therapy group. This suggests a strong link between the specific drug combination and better short-term stability for these patients.
Important limitations must be considered. The study was conducted at a single center and used existing records rather than a planned trial. Because the design was retrospective, it cannot prove that the drugs caused the improvement, only that the two are associated. Readers should wait for larger, prospective studies before considering this approach for routine use.